ProSpective, MultI-Center, Observational PrograM to Assess the Effectiveness of Dual TheraPy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Routine Clinical Settings of the Russian Federation
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Lamivudine (Primary) ; Lopinavir/ritonavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SIMPLE
- Sponsors AbbVie
- 07 Jun 2017 Biomarkers information updated
- 01 Jun 2017 Status changed from active, no longer recruiting to completed.
- 12 Aug 2016 Planned primary completion date changed from 1 May 2017 to 1 Sep 2017.